

Who can participate in the Registry?

- Women diagnosed with migraine who have received VYEPTI any time during their pregnancy or up to 20 weeks prior to becoming pregnant; and/or
- Women diagnosed with migraine who have taken other preventive medication for migraine during their pregnancy and/or up to 1 week (depending on medication) prior to becoming pregnant. Preventive medications can include, but are not limited to, amitriptyline, venlafaxine, divalproex, topiramate, valproate, atenolol, metoprolol, propranolol, nadolol, timolol, and onabotulinumtoxin A.

For more information about Vyepti, please see Patient Information at the following location:
https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_ppi_us_en.pdf

The VYEPTI Pregnancy Registry

To speak to a Pregnancy Registry representative,
contact the VYEPTI Pregnancy Registry
Coordinating Center toll-free at: **1-855-810-8549**.

For more information visit:

www.vyeptipregnancyregistry.lundbeck.com



The VYEPTI Pregnancy Registry

Patient Information Pamphlet

What is the VYEPTI Pregnancy Registry?

H. Lundbeck A/S (Lundbeck), the manufacturer of eptinezumab-jjmr (VYEPTI®), is conducting the VYEPTI Pregnancy Registry. This is an observational study of maternal, fetal and infant safety in pregnant women treated with VYEPTI in the United States. The purpose of this study is to collect and process data of pregnant women and their unborn and newborn baby(ies) to assess the use of VYEPTI or other preventive migraine medications in pregnancy. In addition, infant health outcomes will be collected up to the infant's first birthday.

During the development of pharmaceutical products, pregnant women are typically excluded from clinical trials and therefore, limited information is available on the use of VYEPTI during pregnancy. Information obtained from this study may assist health care providers and future pregnant women in weighing the risks and benefits of being treated with VYEPTI during pregnancy.

This is a non-interventional, national, cohort study which means you and your infant(s) will continue to receive healthcare as decided by your healthcare provider(s). Participation in this study will not impact you or your infant(s)'s treatment or care. You and your infant(s) will continue to receive standard care as decided by your healthcare provider(s).

Why should I participate in this Registry?

Your participation is voluntary, but you and your infant(s) will provide important information that will help Lundbeck evaluate the use of VYEPTI and other preventive migraine medications in women during their pregnancy and follow their infant(s)'s growth and development up to their first birthday. The success of the Registry is dependent upon the participation of eligible patients and healthcare providers. There will be no change to the care you receive from your healthcare provider, as this is an observational study.

How do I enroll?

To learn more about the VYEPTI Pregnancy Registry and to find out if you qualify for enrollment:

- Contact the VYEPTI Pregnancy Registry Coordinating Center toll-free at **1-855-810-8549** -OR-
- Email VYEPTI Pregnancy Registry Coordinating Center at vyeptipregnancyregistry@ubc.com -OR-
- Visit the study website at www.vyeptipregnancyregistry.lundbeck.com -OR-
- You may also ask your healthcare provider to support you with enrollment

If you are eligible and would like to participate, you will be asked to provide your informed consent to acknowledge your understanding of the Registry and to provide your permission for your personal and infant(s)'s healthcare information to be collected. If you are interested in participating, please contact the VYEPTI Pregnancy Registry Coordinating Center. After consent is received, a Registry representative will contact your healthcare provider to confirm your personal health information.

What will my participation involve once I am enrolled?

Your participation in the Registry will last throughout your pregnancy and up to one year after your delivery date. You will be contacted by the Pregnancy Registry Coordinating Center during the last month of the second trimester of your pregnancy, on the estimated date of delivery, when your baby is 6 and 12 months of age, and periodically throughout the study to collect medication usage from your participant diary.

You will be asked to record any information related to medication you are taking during the Registry in a patient diary electronically via an app or in a paper-based form.

A Registry representative will also contact your healthcare provider and your infant(s)'s pediatrician to determine if there are any changes in your and your baby(ies)'s health status. If enrolled, you can choose to end your participation at any time for any reason.

Will my privacy be protected?

All personal and medical information will be kept strictly confidential. Information about your health while you are enrolled in the VYEPTI Pregnancy Registry will be kept anonymous and any identifying information will not be used.